SG10201907249WA - Human cytomegalovirus comprising exogenous antigens - Google Patents
Human cytomegalovirus comprising exogenous antigensInfo
- Publication number
- SG10201907249WA SG10201907249WA SG10201907249WA SG10201907249WA SG10201907249WA SG 10201907249W A SG10201907249W A SG 10201907249WA SG 10201907249W A SG10201907249W A SG 10201907249WA SG 10201907249W A SG10201907249W A SG 10201907249WA SG 10201907249W A SG10201907249W A SG 10201907249WA
- Authority
- SG
- Singapore
- Prior art keywords
- human cytomegalovirus
- exogenous antigens
- antigens
- vectors
- exogenous
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 239000013598 vector Substances 0.000 abstract 2
- 101100315698 Human cytomegalovirus (strain Merlin) UL131A gene Proteins 0.000 abstract 1
- 101150088910 UL82 gene Proteins 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002963 ganciclovir Drugs 0.000 abstract 1
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
Abstract
HUMAN CYTOMEGALOVIRUS COMPRISING EXOGENOUS ANTIGENS Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71. No suitable figure
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462025348P | 2014-07-16 | 2014-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201907249WA true SG10201907249WA (en) | 2019-09-27 |
Family
ID=53776978
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201907249WA SG10201907249WA (en) | 2014-07-16 | 2015-07-16 | Human cytomegalovirus comprising exogenous antigens |
SG11201700315YA SG11201700315YA (en) | 2014-07-16 | 2015-07-16 | Human cytomegalovirus comprising exogenous antigens |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700315YA SG11201700315YA (en) | 2014-07-16 | 2015-07-16 | Human cytomegalovirus comprising exogenous antigens |
Country Status (16)
Country | Link |
---|---|
US (3) | US10428118B2 (en) |
EP (2) | EP4194558A1 (en) |
JP (4) | JP6487026B2 (en) |
KR (3) | KR101996427B1 (en) |
CN (2) | CN107002048B (en) |
AP (1) | AP2017009743A0 (en) |
AU (2) | AU2015289560B2 (en) |
BR (1) | BR112017000696B1 (en) |
CA (2) | CA2955306C (en) |
EA (1) | EA039174B1 (en) |
IL (1) | IL250130B (en) |
MX (2) | MX2017000658A (en) |
NZ (1) | NZ728208A (en) |
SG (2) | SG10201907249WA (en) |
UA (1) | UA120938C2 (en) |
WO (1) | WO2016011293A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2569436B8 (en) | 2010-05-14 | 2019-10-30 | Oregon Health & Science University | Recombinant hcmv and rhcmv vectors and uses thereof |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CA2904001C (en) | 2013-03-05 | 2021-07-13 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of t cell targeting |
WO2016011293A1 (en) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
MA40783A (en) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | HIV VACCINES CONTAINING ONE OR MORE POPULATION EPISENSUS ANTIGENS |
CN114317611A (en) | 2015-02-10 | 2022-04-12 | 俄勒冈健康与科学大学 | Methods and compositions useful for generating atypical CD8+ T cell responses |
JP7133468B2 (en) | 2015-11-20 | 2022-09-08 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ | CMV vectors containing microRNA recognition elements |
US20200182884A1 (en) * | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
SG11201903340TA (en) * | 2016-10-18 | 2019-05-30 | Univ Oregon Health & Science | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
WO2020014222A2 (en) * | 2018-07-09 | 2020-01-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Viral promoters and compositions and methods of use thereof |
GB201906104D0 (en) * | 2019-05-01 | 2019-06-12 | Univ Plymouth | Intrinsic systems for viral vector transgene regulation |
TW202319070A (en) * | 2021-08-31 | 2023-05-16 | 美商維爾生物科技股份有限公司 | Methods for producing cmv vectors |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
WO1988010311A1 (en) | 1987-06-26 | 1988-12-29 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene and use thereof |
US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
EP0521427A1 (en) | 1991-07-05 | 1993-01-07 | American Cyanamid Company | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus |
AU7192394A (en) | 1993-07-19 | 1995-02-20 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
WO1995030019A1 (en) | 1994-04-29 | 1995-11-09 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
JPH11500014A (en) | 1995-02-21 | 1999-01-06 | キャンタブ ファーマシューティカルズ リサーチ リミティド | Viral preparations, vectors, immunogens, and vaccines |
AU712415B2 (en) | 1995-04-04 | 1999-11-04 | Cell Genesys, Inc. | Transplantation of genetically modified cells having low levels of class I MHC proteins on the cell surface |
ES2237800T3 (en) | 1996-07-31 | 2005-08-01 | Ortho-Mcneil Pharmaceutical, Inc. | IDENTIFICATION OF GENES OF THE HUMAN CITOMEGALOVIRUS INVOLVED IN THE RETRO-REGULATION OF THE EXPRESSION OF HEAVY CHAINS OF CLASS I OF THE CMH. |
US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
DE19733364A1 (en) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Method of cloning a large virus genome |
WO1999007869A1 (en) | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
CA2437201C (en) | 2001-02-02 | 2008-11-18 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
CA2438322A1 (en) | 2001-02-21 | 2002-08-29 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
CA2461056A1 (en) | 2001-09-20 | 2003-03-27 | Glaxo Group Limited | Hiv-gag codon-optimised dna vaccines |
US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
US20060073123A1 (en) | 2002-04-30 | 2006-04-06 | Jie Mi | Adenovirus vectors for immunotherapy |
DE10232322A1 (en) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Virally encoded CxC determine the tissue tropism of HCMV |
US7407744B2 (en) | 2003-07-25 | 2008-08-05 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors |
CA2837748C (en) | 2004-05-25 | 2016-03-08 | Oregon Health And Science University | Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors |
EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
WO2006004661A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
EP1888622A1 (en) | 2005-05-23 | 2008-02-20 | Oxxon Therapeutics Ltd. | Compositions for inducing an immune response against hepatitis b |
AU2006284756B2 (en) | 2005-08-31 | 2012-06-07 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
US20100142823A1 (en) | 2007-03-07 | 2010-06-10 | Ze Wang | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
BRPI0814060A2 (en) | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | LINKING PEPTIDES HAVING A SPECIFIC BINDING AREA ARRANGED IN C-TERMINAL |
DK2215117T4 (en) | 2007-10-30 | 2018-04-09 | Genentech Inc | ANTISTO PURIFICATION BY CATION CHANGE CHROMATOGRAPHY |
EP2403527A4 (en) | 2009-03-06 | 2012-11-14 | Sinai School Medicine | Live attenuated influenza virus vaccines comprising microrna response elements |
EA201270662A1 (en) | 2009-12-23 | 2013-01-30 | 4-Антибоди Аг | BINDING ELEMENTS FOR HUMAN CYTAMEGALOVIRUS |
WO2011093858A1 (en) | 2010-01-27 | 2011-08-04 | Oregon Health & Science University | Cytomegalovirus-based immunogenic preparations |
JP2011177071A (en) * | 2010-02-26 | 2011-09-15 | Aichi Prefecture | Attenuated hcmv and use thereof as vaccine |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
US9078867B2 (en) | 2010-05-05 | 2015-07-14 | Christian Thirion | Vaccine against beta-herpesvirus infection and use thereof |
EP2569436B8 (en) | 2010-05-14 | 2019-10-30 | Oregon Health & Science University | Recombinant hcmv and rhcmv vectors and uses thereof |
CA2832109C (en) * | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
TWI570240B (en) | 2011-09-09 | 2017-02-11 | 默沙東公司 | A conditional replicating cytomegalovirus as a vaccine for cmv |
US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
MX2015005505A (en) * | 2012-10-30 | 2016-01-08 | Redvax Gmbh | Recombinant particle based vaccines against human cytomegalovirus infection. |
CA2904001C (en) | 2013-03-05 | 2021-07-13 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of t cell targeting |
WO2016011293A1 (en) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
CN114317611A (en) | 2015-02-10 | 2022-04-12 | 俄勒冈健康与科学大学 | Methods and compositions useful for generating atypical CD8+ T cell responses |
JP7133468B2 (en) | 2015-11-20 | 2022-09-08 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ | CMV vectors containing microRNA recognition elements |
WO2017223146A1 (en) | 2016-06-22 | 2017-12-28 | Aeras | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
US20200182884A1 (en) | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
SG11201903340TA (en) | 2016-10-18 | 2019-05-30 | Univ Oregon Health & Science | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
-
2015
- 2015-07-16 WO PCT/US2015/040807 patent/WO2016011293A1/en active Application Filing
- 2015-07-16 SG SG10201907249WA patent/SG10201907249WA/en unknown
- 2015-07-16 CN CN201580045987.1A patent/CN107002048B/en active Active
- 2015-07-16 UA UAA201701206A patent/UA120938C2/en unknown
- 2015-07-16 JP JP2017502666A patent/JP6487026B2/en active Active
- 2015-07-16 BR BR112017000696-0A patent/BR112017000696B1/en active IP Right Grant
- 2015-07-16 KR KR1020177004156A patent/KR101996427B1/en active IP Right Grant
- 2015-07-16 EA EA201790167A patent/EA039174B1/en unknown
- 2015-07-16 US US15/326,444 patent/US10428118B2/en active Active
- 2015-07-16 EP EP22209713.1A patent/EP4194558A1/en active Pending
- 2015-07-16 NZ NZ728208A patent/NZ728208A/en unknown
- 2015-07-16 AP AP2017009743A patent/AP2017009743A0/en unknown
- 2015-07-16 EP EP15745663.3A patent/EP3169787A1/en not_active Withdrawn
- 2015-07-16 SG SG11201700315YA patent/SG11201700315YA/en unknown
- 2015-07-16 KR KR1020197018702A patent/KR102205348B1/en active IP Right Grant
- 2015-07-16 KR KR1020217001036A patent/KR102403547B1/en active IP Right Grant
- 2015-07-16 CN CN202110650460.9A patent/CN113528466A/en active Pending
- 2015-07-16 AU AU2015289560A patent/AU2015289560B2/en active Active
- 2015-07-16 CA CA2955306A patent/CA2955306C/en active Active
- 2015-07-16 MX MX2017000658A patent/MX2017000658A/en unknown
- 2015-07-16 CA CA3113595A patent/CA3113595A1/en active Pending
-
2017
- 2017-01-15 IL IL250130A patent/IL250130B/en active IP Right Grant
- 2017-01-16 MX MX2021006730A patent/MX2021006730A/en unknown
-
2018
- 2018-11-26 AU AU2018267687A patent/AU2018267687B2/en active Active
-
2019
- 2019-02-19 JP JP2019027030A patent/JP6925376B2/en active Active
- 2019-08-20 US US16/545,561 patent/US10995121B2/en active Active
-
2021
- 2021-03-26 US US17/214,598 patent/US11692012B2/en active Active
- 2021-08-03 JP JP2021127653A patent/JP7299275B2/en active Active
-
2023
- 2023-06-15 JP JP2023098250A patent/JP2023116706A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006730A (en) | Human cytomegalovirus comprising exogenous antigens. | |
MX2023003246A (en) | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses. | |
PH12018500964A1 (en) | Modified friedreich ataxia genes and vectors for gene therapy | |
IL257009A (en) | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation | |
MX2022006513A (en) | Expression constructs and methods of genetically engineering methylotrophic yeast. | |
MX2018005286A (en) | Genetic construct. | |
EP3222728A4 (en) | Method for regulating gene expression using cas9 protein expressed from two vectors | |
MX2023004479A (en) | Multiple vector system and uses thereof. | |
SG10201810150UA (en) | Compositions and methods for enhanced gene expression in cone cells | |
SA517380883B1 (en) | An Improved Expression Cassette for Packaging and Expression of Variant Factor Viii for The Treatment of Hemostasis Disorders | |
MX2017016400A (en) | Vectors for use in an inducible coexpression system. | |
MX2020010694A (en) | Gene therapy for retinitis pigmentosa. | |
MY181175A (en) | Therapeutic hpv16 vaccines | |
MX2019002699A (en) | Gene therapy for patients with fanconi anemia. | |
MX2018001055A (en) | Promoters for enhancing expression in poxviruses. | |
MX2020003385A (en) | Replication competent adenoviral vectors. | |
IL279281A (en) | Optimizing bag3 gene therapy | |
IL280165A (en) | Glucocerebrosidase gene therapy | |
MX2019006552A (en) | Gene therapy for mucopolysaccharidosis, type i. | |
WO2018183692A8 (en) | Vectors and compositions for treating hemoglobinopathies | |
MX2017004769A (en) | Promoter and regulatory elements for improved expression of heterologous genes in host cells. | |
GB2572716B (en) | Gene Therapy Vector System and Prodrug Genes | |
EP3847259A4 (en) | Gene therapy based on vector vtvaf17 | |
MX2019006551A (en) | Gene therapy for mucopolysaccharidosis, type ii. | |
TH1701000216A (en) | The human cytomegalovirus is composed of exogenous antigens. |